Use of cationic steroidal antimicrobial compounds to deactivate coronavirus

1. A method of treating a coronavirus infection in a subject, the method comprising:

providing a deactivation composition including a cationic steroidal antimicrobial (CSA) compound in a carrier, wherein the CSA compound has a chemical structure of Formula IV, or salt thereof:

where,

R 3 , R 7 , and R 12 are independently selected from the group consisting of aminoalkyloxy, aminoalkylcarboxy, aminoalkylurethanyl, aminoalkenyl-urethanyl, aminoalkynylurethanyl, and aminoarylurethanyl; and

R 18 is selected from the group consisting of alkylaminoalkyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, alkylcarbonylalkyl, di(alkyl)aminoalkyl, alkylcarboxyalkyl, hydroxyalkyl, terpenylcarboxyalkyl, terpenylcarbonyloxyalkyl, terpenylcarboxamido-alkyl, terpenylaminoalkyl, and terpenyloxyoalkyl; and

administering the deactivation composition to the subject, wherein the deactivation composition treats the coronavirus infection in the subject by deactivating coronavirus virions in the subject or that come into contact with the subject.

2. The method of claim 1 , wherein the subject is a human, livestock animal, poultry, pet, laboratory animal, or zoo animal.

3. The method of claim 1 , wherein deactivation composition is administered topically.

4. The method of claim 1 , wherein the deactivation composition is provided in the form of a liniment, salve, lotion, ointment, cream, powder, soap, wash, or spray.

5. The method of claim 1 , wherein the deactivation composition is administered via inhalation.

6. The method of claim 5 , wherein the deactivation composition is provided as an aqueous solution capable of being nebulized.

7. The method of claim 5 , wherein the deactivation composition is administered using a metered-dose inhaler, a nebulizer, and/or a dry powder dispersion device.

8. The method of claim 5 , wherein the carrier comprises one or more of saline solution, bulking powders, carbohydrates, disaccharides, oligo- or polysaccharides, alcohols or polyalcohols, salts, amino acids, buffers, or combinations thereof.

9. The method of claim 1 , wherein the deactivation composition is administered orally or parenterally.

10. The method of claim 1 , wherein the carrier comprises one or more of water, alcohol, other organic solvents, an emulsion, or combinations thereof.

11. The method of claim 1 , wherein the CSA compound is selected from the group consisting of CSA-13, CSA-27, CSA-28, CSA-30, CSA-31, CSA-32, CSA-33, CSA-34, CSA-35, CSA-36, CSA-37, CSA-41, CSA-42, CSA-43, CSA-44, CSA-45, CSA-47, CSA-49, CSA-50, CSA-51, CSA-52, CSA-56, CSA-61, CSA-90, CSA-131, CSA-136, CSA-137, CSA-138, CSA-141, CSA-142, CSA-144, CSA-145, CSA-146, CSA-148, CSA-190, CSA-191, CSA-192, CSA-255, CSA-256, and CSA-257.

12. A method of treating a coronavirus infection in a subject, the method comprising:

providing a deactivation composition including one or more cationic steroidal antimicrobial (CSA) compounds in a carrier, the one or more CSA compounds having a chemical structure of Formula IV, or salt thereof:

where,

R 3 , R 7 , and R 12 are independently selected from the group consisting of aminoalkyloxy and aminoalkylcarboxy; and

R 18 is selected from the group consisting of alkylaminoalkyl, di(alkyl)aminoalkyl, and alkylcarboxyalkyl; and

administering the deactivation composition to the subject, wherein the deactivation composition treats the coronavirus infection in the subject by deactivating coronavirus virions in the subject or that come into contact with the subject.

13. The method of claim 12 , wherein the subject is a human, livestock animal, poultry, pet, laboratory animal, or zoo animal.

14. The method of claim 12 , wherein the carrier comprises one or more of saline solution, bulking powders, carbohydrates, disaccharides, oligo- or polysaccharides, alcohols or polyalcohols, salts, amino acids, buffers, or combinations thereof and the deactivation composition is administered via inhalation.

15. The method of claim 12 , wherein the deactivation composition is provided as an aqueous solution capable of being nebulized.

16. The method of claim 15 , wherein the deactivation composition is administered using a metered-dose inhaler, a nebulizer, and/or a dry powder dispersion device.

17. The method of claim 12 , wherein the carrier comprises one or more of water, alcohol, other organic solvents, an emulsion, or combinations thereof.

18. The method of claim 12 , wherein the CSA compound is selected from the group consisting of CSA-13, CSA-18, CSA-22, CSA-38, CSA-43, CSA-44, CSA-45, CSA-46, CSA-53, CSA-90, CSA-91, CSA-92, CSA-93, CSA-93, CSA-97, CSA-98, CSA-99, CSA-103, CSA-130, CSA-131, CSA-132, CSA-133, CSA-134, CSA-135, CSA-136, CSA-137, CSA-138, CSA-141, CSA-142, CSA-144, CSA-145, CSA-146, CSA-148, CSA-190, CSA-191, CSA-192, CSA-192MS, CSA-255, CSA-256, CSA-257, and CSA-258.

19. A method of treating a coronavirus infection in a subject, the method comprising:

providing a deactivation composition including one or more cationic steroidal antimicrobial (CSA) compounds in a carrier, wherein the one or more CSA compounds are selected from the group consisting of: CSA-13, CSA-43, CSA-44, CSA-45, CSA-90, CSA-131, CSA-136, CSA-137, CSA-138, CSA-141, CSA-142, CSA-144, CSA-145, CSA-146, and CSA-148; and

administering the deactivation composition to the subject, wherein the deactivation composition treats the coronavirus infection in the subject by deactivating coronavirus virions in the subject or that come into contact with the subject.

20. The method of claim 19 , wherein the carrier comprises one or more of saline solution, bulking powders, carbohydrates, disaccharides, oligo- or polysaccharides, alcohols or polyalcohols, salts, amino acids, buffers, or combinations thereof and the deactivation composition is administered via inhalation.